Piracetam
Piracetam, the active substance of Lucetam, is a nootropic agent, which means it stimulates brain metabolism. It reduces blood viscosity, increases blood flow through the brain vessels without vasodilating effects, and also increases oxygen utilization and glucose consumption in ischemic brain tissue.
Before taking Lucetam, tell your doctor or pharmacist:
Tell your doctor about all medicines you are taking, or have recently taken, and any medicines you plan to take.
Remember to inform your doctor if you are taking thyroid hormones or anticoagulant medications. Concomitant use of these medicines with Lucetam requires close medical supervision or dose modification.
If you are pregnant or breastfeeding, think you may be pregnant, or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.
Pregnancy
Lucetam should only be used during pregnancy if clearly necessary. The doctor will only prescribe this medicine if the benefits of its use in individual cases outweigh the risk to the baby.
Breastfeeding
Piracetam is excreted in human milk. Therefore, Lucetam should not be used during breastfeeding, or breastfeeding should be discontinued during treatment with Lucetam.
Given the adverse events observed during the use of Lucetam, the medicine may affect the ability to drive and use machines, which should be taken into account. In this regard, the doctor will determine the appropriate restrictions.
Always take this medicine exactly as your doctor or pharmacist has told you. If you are not sure, ask your doctor or pharmacist.
Recommended Dose
The dose and duration of treatment should be determined individually by the doctor, depending on the type and severity of the disease, age, and other diseases.
Tablets should be taken with food or on an empty stomach and washed down with 100-200 ml of liquid.
It is recommended to divide the daily dose into 2-4 equal parts.
Recommended daily doses depending on the indication:
Treatment of Central Nervous System-Derived Muscle Tremors (Cortical Myoclonus):
The recommended initial dose is 7.2 g per day. If necessary, this dose can be increased by 4.8 g every 3-4 days, up to a maximum dose of 24 g, given in 2 or 3 divided doses.
Treatment of Dizziness
The recommended daily dose ranges from 2.4 g to 4.8 g, given in 2 or 3 divided doses.
In cases of renal impairment, dose adjustment may be necessary.
To Improve Learning Results in Children with Learning Problems and Dyslexic Disorders (in Combination with Other Methods):
In adolescents and children from 8 years of age, the recommended daily dose is approximately 3.2 g, given in 2 divided doses. It is used in combination with speech therapy.
If you have taken more than the recommended dose of Lucetam, seek medical attention immediately.
Do not take a double dose to make up for a missed dose. If you miss a dose of Lucetam at the scheduled time, take the missed dose as soon as possible before the next dose. If it is already time for the next dose, skip the missed dose, otherwise, there is a risk of overdose after taking 2 doses at once.
Do not stop taking Lucetam without first consulting your doctor.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
Like all medicines, Lucetam can cause side effects, although not everybody gets them.
If you experience any of the following symptoms, stop taking Lucetam and seek immediate medical attention:
The following side effects have been reported:
Common Side Effects(may affect up to 1 in 10 people):
Hyperkinesia (involuntary and excessive movement, usually of skeletal muscles), weight gain, nervousness.
Uncommon Side Effects(may affect up to 1 in 100 people):
Weakness, somnolence, depression.
Side Effects of Unknown Frequency(frequency cannot be estimated from the available data):
Coagulation disorders, excitement, anxiety, confusion, hallucinations, ataxia (coordination disorders), balance disorders, exacerbation of epilepsy, headache, insomnia, dizziness, abdominal pain, epigastric pain, diarrhea, nausea, and vomiting, skin inflammation, itching.
If you experience any side effects, including those not listed in this leaflet, tell your doctor or pharmacist. Side effects can be reported directly to the Department of Adverse Reaction Monitoring of Medicinal Products, Medical Devices, and Biocidal Products
Al. Jerozolimskie 181C
02-222 Warsaw
Phone: +48 22 49 21 301
Fax: +48 22 49 21 309
Website: https://smz.ezdrowie.gov.pl
Side effects can also be reported to the marketing authorization holder.
By reporting side effects, you can help provide more information on the safety of this medicine.
Store in a temperature below 30°C.
Store in a place out of sight and reach of children.
Do not use the medicine after the expiry date stated on the carton.
The expiry date refers to the last day of that month.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. This will help protect the environment.
The active substance is piracetam.
Each film-coated tablet contains 400 mg, 800 mg, or 1200 mg of piracetam.
The other ingredients are: magnesium stearate, povidone K-30, coating (macrogol 6000, dibutyl sebacate, titanium dioxide (E171), talc, ethylcellulose, hypromellose).
White or almost white, oval, biconvex tablets with the inscription "E 241" (400 mg tablets), "E 242" (800 mg tablets), or "E 243" (1200 mg tablets) on one side.
The 800 mg tablets have a score line on both sides. The score line on the tablet is only to facilitate breaking and does not divide the tablet into equal doses.
400 mg and 800 mg tablets: orange glass bottles with a plastic cap, equipped with a tablet retaining element, in a carton box, with an enclosed patient information leaflet, containing:
400 mg: 60 film-coated tablets;
800 mg: 30 or 60 film-coated tablets.
1200 mg tablets: orange glass bottle with a plastic child-resistant cap, in a carton box, with an enclosed patient information leaflet, containing 20 or 60 film-coated tablets.
EGIS Pharmaceuticals PLC
Keresztúri út 30-38
1106 Budapest
Hungary
EGIS Pharmaceuticals PLC
Mátyás király u. 65
9900 Körmend
Hungary
For further information, please contact the representative of the marketing authorization holder:
EGIS Polska Sp. z o.o.
ul. Komitetu Obrony Robotników 45D
02-146 Warsaw
Phone: +48 22 417 92 00
Date of Last Revision of the Leaflet:07.10.2022
Need help understanding this medicine or your symptoms? Online doctors can answer your questions and offer guidance.